The FDA has made a decision regarding hormone replacement therapy (HRT) that may impact women's health and longevity. However, the implications of this decision are being debated, with some medical professionals expressing disagreement and others suggesting it could transform menopause care. The move appears to involve a change to the labeling of estrogen, potentially altering its use in menopause hormone therapy.